| Project/Area Number |
26462407
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
古瀬 洋 浜松医科大学, 医学部附属病院, 講師 (00345828)
本山 大輔 浜松医科大学, 医学部附属病院, 診療助教 (00727787)
高岡 直央 浜松医科大学, 医学部, 特任研究員 (30467229)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | FABP7 / ドコサテトラエン酸 / EPA / GPD1 / GPD2 / 腎癌 / トリアシルグリセロール生合成系 / 脳型脂肪酸結合タンパク質 |
|---|
| Outline of Final Research Achievements |
Expression of brain-type fatty acid-binding protein (FABP7) is specifically on renal cell carcinoma (RCC). FABP7 would be worked to stimulation or repression of cell proliferation according to the influence of other factors. It suggests the complicated outbreak mechanism of cancer became clear. In addition, FABP7 has a possibility to be applicable for a treatment target of RCC, because a neoplasia promotion effect was seen by the expression of FABP7. Further, the glycerol-3-phosphate dehydrogenase 1 (GPD1) is on the metabolic pathway that links the triglyceride synthetic pathway to the glycolytic pathway. Expression of GPD1 was weaker in RCC than a kidney tissue. It suggests that GPD1 may be available for the treatment of RCC.
|
